Markets
Bladder-Cancer Trial Meets Main Goal, Sending CG Oncology Stock Up 11%
The company expects its broadened FDA application by the end of March 2027, following results showing a 68% reduction in recurrence risk compared with surveillance.
CG Oncology (CGON) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The company expects its broadened FDA application by the end of March 2027, following results showing a 68% reduction in recurrence risk compared with surveillance.
SEC Filings
The drugmaker plans two FDA applications in 2027, including a broader initial request covering cancers that did not respond to BCG.
Markets
The bladder-cancer drug developer expects its $984.5 million reserve to fund operations through 2029 as trial readouts approach.
SEC Filings
Research costs rose as the company prepares trial readouts and an FDA application, with cash expected to fund operations through 2029.